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however, that they did not report effects of pyridoxamine
on the root cause of vaso-occlusion, i.e., the sickle red
blood cells (RBC). Especially at this time, when we know
clearly that sickle RBC are deficient in anti-oxidant capac-
ity,15 and that oxidative pathways in RBC promote vaso-
occlusion,13 understanding the effects of anti-oxidant
therapies on sickle RBC biology, the root cause of SCD,
should be prioritized.
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So far this century we have witnessed the introduc-tion of a number of targeted therapies, developedthrough rational drug design, which have changed
cancer treatment and resulted in improved outcomes for
many patients, including those with a spectrum of chron-
ic lymphoid and myeloid malignancies.1,2 However,
despite improved understanding of the biology of acute
myeloid leukemia (AML), similar scale benefits by target-
ing kinases and other intracellular and surface proteins
have yet to be realized, and the prognosis for patients
with AML remains poor. Moreover, cytotoxic drugs and
therapies developed in the last century currently remain
the backbone of AML treatment, and as AML primarily
affects the elderly, many of whom are therefore frail with
multiple co-morbidities, the clinical application of such
curative therapies is somewhat limited.3 Furthermore,
even in those fit enough for intensive chemotherapy,
both relapse and treatment resistance are common, due
to the aggressive nature of the disease. The search there-
fore continues for biology-driven targeted treatments for
patients with AML which can be delivered to all, and at
the same time increase remission rates, reduce relapses
and prevent treatment resistance. The expectation is that
these therapies will come from advances in the under-
standing of the biology of AML.
Tyrosine kinases are known to play a role in the tumori-
genesis of both solid tumors and hematological malignan-
cies and they therefore present a potential treatment target.4
In particular, Bruton tyrosine kinase (BTK) inhibitors have
been shown to be effective in the treatment of a number of
hematologic malignancies including chronic lymphocytic
leukemia and lymphomas.5-7 BTK is a non-receptor tyrosine
kinase with an important role in both normal and malig-
nant hematopoiesis.8 Its expression and phosphorylation
are high in AML and BTK inhibition with ibrutinib has
been shown to have an anti-leukemic effect.9 Moreover,
many other tyrosine kinases have been shown to be acti-
vated in AML and hematologic malignancies including
SYK, FLT3, MAPK, PI3K and AKT.10,11 This knowledge sup-
ports further exploration of tyrosine kinase inibitors in the
treatment of AML.
In this issue of Haematologica, Soncini et al. explore the
potential role of ARQ531, a reversible small molecule
inhibitor of BTK and a number of other kinases, in the man-
agement of AML12 (Figure 1). BTK was shown to be consti-
tutively active in a range of different subtypes of AML, sug-
gesting that targeting it could have a broad clinical applica-
tion in all patients with AML. ARQ531 was observed to
have dose-dependent anti-leukemic activity by inducing
apoptosis in both AML cell lines and primary AML cells.
The effect of ARQ531 was superior to that of treatment
with ibrutinib and this was likely due to the broader mode
of action of ARQ531. While ARQ531 has anti-BTK activity
its action does not appear to be dependent on BTK and it
was shown to inhibit a number of other oncogenic path-
ways as well. Thus, ARQ531 treatment reduced cell viabil-
ity even after knock-down of BTK in AML cells. 
We know that AML is heavily reliant on its tumor
microenvironment13 and disrupting this relationship is a cru-
cial step in improving AML treatments and therefore out-
comes for patients. When considering effectiveness of new
treatments, we must therefore assess whether they are able
to target leukemic cells within this supportive environment.
Soncini et al. were able to demonstrate that the anti-
leukemic activity of ARQ531 was preserved when AML
cells were co-cultured with mesenchymal stromal cells.
Moreover, the viability of the mesenchymal stromal cells as
well as that of other non-malignant cells, including
hematopoietic stem cells, was not affected by treatment
with ARQ531. This is important when considering the
potential toxicity of a drug as there is a need to protect non-
malignant cells in order to prevent side effects and reduce
treatment-related morbidity and mortality. 
A number of oncogenic pathways have been shown to
drive leukemogenisis, disease progression and treatment
resistance. In addition to upregulation of BTK, these include
activation of the mitogen-activated protein kinase (MAPK)
pathway and dysregulation of the hematopoietic transcrip-
tional factor MYB, which have been implicated in the
pathogensis of AML.14,15 The mode of action of ARQ531 is
complex and genetic analysis revealed that it inhibits a
number of different oncogenic pathways in AML. The data
published in this issue show that ARQ531 disrupts the
oncogenic MAPK pathway by inhibiting ERK and AKT
activation as well as downregulating MYC. Furthermore,
ARQ531 was shown to deregulate and promote degrada-
tion of the oncogenic driver MYB. Interestingly the action
on all of these pathways, including BTK, MAPK and MYB,
as well, potentially, as others not yet identified, appears to
have a cumulative effect on cell viability. Inhibition of each
pathway individually is less effective in reducing cell viabil-
ity than using ARQ531, suggesting that additional path-
ways are important in this drug’s mode of action. It is clear
that leukemogenesis relies on the dysregulation of multiple
oncogenic pathways and therefore targeting only one of
these is not sufficient to achieve cell death and reduce
tumor growth. A drug that has the ability to target a num-
ber of these pathways does, therefore, have greater poten-
tial to effectively eliminate malignant cells and at the same
time has little or no lasting effect on non-malignant cells. 
To demonstrate this Soncini et al. designed an in vivo
experiment using a patient-derived AML mouse model.
Following engraftment of immunocompromised mice with
primary AML cells they demonstrated that treatment with
ARQ531 impaired AML engraftment, reduced tumor bur-
den and improved the animals’ survival. Furthermore, there
were no signs of toxicity, suggesting that ARQ531 could be
an effective and well-tolerated treatment for AML in the
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Figure 1. Schematic representation of the mechanism of action of ARQ531 in acute myeloid leukemia. BTK: Bruton tyrosine kinase; ERK: extracellular-signal-relat-
ed kinase; MAPK: mitogen-activated protein kinase; AML: acute myeloid leukemia. 
future. However, a note of caution is that many potential
therapies have been shown to have in vivo efficacy in AML,
but when tested clinically have had little or no effect on this
disease.
In conclusion, by targeting a number of different onco-
genic pathways, in vitro and in vivo treatment with ARQ531
results in reduced AML cell viability, reduced tumor growth
and improved survival of animals. The research by Soncini
et al. suggests that a multi-targeted inhibitor such as
ARQ531 is required to impair AML survival effectively;
since this drug does not rely specifically on high expression
of BTK or other tyrosine kinases it could be widely applica-
ble to different subtypes of AML.
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The concept of precision medicine applied to humantumors implies the personalized tailoring of clinicalmanagement and treatment choices according to
the status of an array of molecular biomarkers, in con-
junction with other patient features.1 In chronic lympho-
cytic leukemia (CLL), the extensive body of genetic data
that have been accumulated in recent years has led to the
identification of many new molecular biomarkers with
prognostic value. However, only a few of these serve the
role of true predictors for choosing the most appropriate
treatment for any given patient.1,2 The active search for
molecular predictors in CLL is becoming increasingly
more important in the current therapeutic landscape of
the disease, that ranges from chemo-immunotherapy
with both old and newer monoclonal antibodies (mAb)
to chemo-free options based on B-cell receptor (BCR)
inhibitors, targeting either Bruton tyrosine kinase or
phosphatidyilinositol-3-kinase, and BCL2 inhibitors.3,4
In this issue of Haematologica, Tausch et al. have ana-
lyzed the prognostic and, more importantly, the predic-
tive role of a panel of gene mutations in the randomized,
phase III COMPLEMENT1 trial comparing chlorambucil
with ofatumumab-chlorambucil in treatment-naïve CLL
patients not eligible for intensive therapy because of age
or comorbidities.5 The COMPLEMENT 1 trial had docu-
mented that addition of the type 1 anti-CD20 mAb ofa-
tumumab to chlorambucil leads to clinically significant
improvement in progression-free survival (PFS) (22.4
months in the arm treated with ofatumumab chlorambu-
cil vs. 13.1 months in the arm treated with single agent
chlorambucil), with a manageable side effect profile.6 But
whether ofatumumab provided an advantage to all
molecular subgroups of CLL remains unexplored.
Remarkably, in the genetic analysis performed by Tausch
et al., mutations of NOTCH1 were seen to predict weak
benefit from the addition of ofatumumab to the chloram-
bucil backbone.5 The NOTCH1 signaling pathway is a
key feature in CLL growth and survival, and is deregulat-
ed by mutations in a sizable fraction of CLL7 (Figure 1).
NOTCH1 mutations in CLL may target either the
autoregulatory PEST domain, or the non-coding 3’-
untranslated region (3’-UTR) sequence.7 In the context of
